Hutchison MediPharma

hmplglobal.com

Hutchison MediPharma (HMP) is a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of over 400 scientists and staff, our pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia, China and Korea. Founded in 2002, HMP's strategic partnerships involve global, innovative companies such as AstraZeneca, Eli Lilly and Nestlé Health Science in oncology and inflammation research & development.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

CEM CORPORATION AND AMBIOPHARM ENTER INTO US PARTNERSHIP FOR GMP PEPTIDE PRODUCTION

CEM Corporation | September 16, 2021

news image

CEM Corporation and AmbioPharm, Inc. are pleased to announce the formation of a partnership to produce GMP peptides for the global market. The partnership includes the exclusive 1Use of CEM's microwave peptide synthesis technology on a large scale for the production of GMP peptides up to several kilograms using its own scalable reactors. The main advantages of this new relationship are the extremely short production times, the ability to efficiently produce more difficult peptide sequences, ...

Read More

PHARMACY MARKET

BOSTON SCIENTIFIC ANNOUNCES PARTNERSHIP DEFINITIVE AGREEMENT TO DIVEST BTG SPECIALTY PHARMACEUTICALS BUSINESS

Boston Scientific | December 02, 2020

news image

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Read More

BUSINESS INSIGHTS

QUOTIENT SCIENCES ACQUIRES ARCINOVA

Quotient Sciences, Arcinova | February 09, 2021

news image

Quotient Sciences, the drug development and manufacturing accelerator, reported that it has procured Arcinova, the U.K.- based multiservice contract development and manufacturing organization (CDMO). With more than 40 years of involvement and 160 representatives, Arcinova gives drug substance, drug item and bioanalysis administrations to more than 200 pharma and biotech clients around the world. The obtaining expands Quotient's administration portfolio and will empower the inc...

Read More

VIEWS AND ANALYSIS

ENTERIS BIOPHARMA PUBLISHES WHITE PAPER EXAMINING FACTORS TO CONSIDER WHILE EVALUATING ORAL ADMINISTRATION OF PEPTIDES

Enteris BioPharma | September 13, 2022

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration." The paper, authored by John Vrettos, PhD, Director of Formulation Developmen...

Read More
news image

BUSINESS INSIGHTS

CEM CORPORATION AND AMBIOPHARM ENTER INTO US PARTNERSHIP FOR GMP PEPTIDE PRODUCTION

CEM Corporation | September 16, 2021

CEM Corporation and AmbioPharm, Inc. are pleased to announce the formation of a partnership to produce GMP peptides for the global market. The partnership includes the exclusive 1Use of CEM's microwave peptide synthesis technology on a large scale for the production of GMP peptides up to several kilograms using its own scalable reactors. The main advantages of this new relationship are the extremely short production times, the ability to efficiently produce more difficult peptide sequences, ...

Read More
news image

PHARMACY MARKET

BOSTON SCIENTIFIC ANNOUNCES PARTNERSHIP DEFINITIVE AGREEMENT TO DIVEST BTG SPECIALTY PHARMACEUTICALS BUSINESS

Boston Scientific | December 02, 2020

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Read More
news image

BUSINESS INSIGHTS

QUOTIENT SCIENCES ACQUIRES ARCINOVA

Quotient Sciences, Arcinova | February 09, 2021

Quotient Sciences, the drug development and manufacturing accelerator, reported that it has procured Arcinova, the U.K.- based multiservice contract development and manufacturing organization (CDMO). With more than 40 years of involvement and 160 representatives, Arcinova gives drug substance, drug item and bioanalysis administrations to more than 200 pharma and biotech clients around the world. The obtaining expands Quotient's administration portfolio and will empower the inc...

Read More
news image

VIEWS AND ANALYSIS

ENTERIS BIOPHARMA PUBLISHES WHITE PAPER EXAMINING FACTORS TO CONSIDER WHILE EVALUATING ORAL ADMINISTRATION OF PEPTIDES

Enteris BioPharma | September 13, 2022

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration." The paper, authored by John Vrettos, PhD, Director of Formulation Developmen...

Read More

Resources

resource image

BUSINESS INSIGHTS, PHARMA TECH

The Pharma Factory of the Future

Video

resource image

BUSINESS INSIGHTS, VIEWS AND ANALYSIS, PHARMACY MARKET

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

Whitepaper

resource image

BUSINESS INSIGHTS, PHARMA TECH

The Pharma Factory of the Future

Video

resource image

BUSINESS INSIGHTS, VIEWS AND ANALYSIS, PHARMACY MARKET

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us